
Researchers at Kaiser Permanente Washington conducted a qualitative pilot study to understand the experiences and decision-making women face as they contemplate the use of antinausea medications during pregnancy.

Researchers at Kaiser Permanente Washington conducted a qualitative pilot study to understand the experiences and decision-making women face as they contemplate the use of antinausea medications during pregnancy.

In this video, Ryan Forrey, PharmD, MS, FASHP is the Senior Manager of Market Development for Hazardous Drugs at BD, discusses USP 800 and surface contamination monitoring.

The Pharmacy Times Salary and Job Satisfaction Survey shows that workload, management, and work/life balance were the 3 top drivers of dissatisfaction.

Tomorrow, pharmacists will be in the spotlight. It is also an opportunity for them to express pride in their work and share aspects of the job that keep them motivated.

Glucagon-like peptide-1 receptor agonists have been gaining popularity to treat diabetes. Does this one provide advantages over competitors?

In response to a growing demand for personalized medicine, the Midwestern University Chicago College of Pharmacy earlier this week announced the establishment of a Pharmacometrics Center of Excellence on the school’s Downers Grove Campus.

This selection of videos includes interviews by Pharmacy Times with key pharmacy professionals along with informative material produced by other educational entities on health conditions of interest to pharmacists.

On National Pharmacist Day, share your #APharmacistIs story on social media.

USP General Chapter , which was published by the United States Pharmacopeial Convention and updated most recently in December 2017, sets forth guidelines for the handling of hazardous drugs in the health care setting with the goal of promoting safety for patients and health care workers.

Patients receiving anticoagulation that need to have an invasive procedure performed may require a temporary interruption in their anticoagulation therapy to limit bleed risk.

Using a drug that increases GABA synthesis and possibly escalates intraneuronal dopamine in a population that is more likely to have behavior health concerns may prove to be an unsafe option.

An FDA-approved mobile application for adults with opioid use disorder (OUD) is now available by prescription. Pear Therapeutics’ reSET-O app aims to increase retention for adults who are in outpatient treatment programs.

A newly study published study aimed to distinguish between uninfected cells and latently infected cells, with hopes that eradicating the latent reservoirs could lead to a cure for the disease.

Sun Pharmaceutical Industries, Inc. (SPI) is voluntarily recalling 3 lots of 10 mg vecuronium bromide for injection and 1 lot of 20 mg vecuronium bromide for injection to the hospital level.

Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Systems now available at a reduced list price of $5,850.

Health care costs in the US represent nearly 20% of the GDP.

The FDA has approved marketing of Lupin Pharmaceuticals’ Lurasidone Hydrochloride Tablets, a generic version of Sunovion Pharmaceuticals, Inc's lurasidone HCl (Latuda) tablets.

Is your life how you imagined it would be, or is it, in reality, more complicated and stressful than you planned? Do you wonder how you managed to achieve all you did including all the patient contacts, and fielding the calls from doctors, too?

Lupin Pharmaceuticals, Inc. has voluntarily recalled 42 of lots of Ceftriaxone for Injection, USP products at the hospital/physician level. These products were found to contain visual grey particulate matter in reconstituted vials.

How can pharmacists implement nonpharmacologic treatments for patients with dementia?

Pharmacy Times’ Ed Cohen, PharmD, FAPha, interviews Miranda Rochol, Healthcare Product Management & Strategy Executive for IQVIA, about opportunities for pharmacy professionals utilizing the company’s services.

The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.

A recall of Torrent Pharmaceuticals Limited’s Losartan Potassium Tablets USP has been expanded to include 8 additional lots. A total of 10 lots are now being recalled at the consumer level, including 2 recalled lots initially announced December 20, 2018.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Michael Ganio, Director, Pharmacy Practice and Quality for the American Society of Health-System Pharmacists addresses a shortage of pharmacy technicians and the evolving role of these technicians in the modern pharmacy.

The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for patients treated with rivaroxaban or apixaban, when anticoagulation reversal is needed.

Everything pharmacists should know about gene therapy medications from current approved products to near and long-term pipeline information.

Study results show a genetic risk variant on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis.